OBJECTIVE: To investigate whether cartilage degeneration is prevented or minimized following intraarticular injections of lubricin derived from human synoviocytes in culture, recombinant human PRG4 (rhPRG4), or human synovial fluid (SF) in a rat model of anterior cruciate ligament (ACL) injury. METHODS: Unilateral ACL transection (ACLT) was performed in Lewis rats (n = 45). Nine animals were left untreated. The remaining rats were given intraarticular injections (50 microl/injection) of either phosphate buffered saline (PBS) (n = 9), human synoviocyte lubricin (200 microg/ml; n = 9), rhPRG4 (200 microg/ml; n = 9), or human SF lubricin (200 microg/ml; n = 9) twice weekly beginning on day 7 after injury. Joints were harvested on day 32 after injury. Histologic analysis was performed using Safranin O-fast green staining, and articular cartilage degeneration was graded using the Osteoarthritis Research Society International (OARSI)-modified Mankin criteria. Histologic specimens were immunoprobed for lubricin and sulfated glycosaminoglycans. A 24-hour urine collection was performed on days 17 and 29 postinjury, and urinary C-terminal telopeptide of type II collagen (CTX-II) levels were measured. RESULTS: Treatment with human synoviocyte lubricin resulted in significantly lower OARSI scores for cartilage degeneration compared with no treatment or PBS treatment (P < 0.05). Increased immunostaining for lubricin in the superficial zone chondrocytes and on the surface of cartilage was observed in lubricin-treated, but not untreated or PBS-treated, joints. On day 17, urinary CTX-II levels in human synoviocyte lubricin- and human SF lubricin-treated animals were significantly lower than those in untreated animals (P = 0.005 and P = 0.002, respectively) and in PBS-treated animals (P = 0.002 and P < 0.001, respectively). CONCLUSION: After treatment with any of the 3 types of lubricin evaluated in this study, a reduction in cartilage damage following ACLT was evident, combined with a reduction in type II collagen degradation. Our findings indicate that intraarticular lubricin injection following an ACL injury may be beneficial in retarding the degeneration of cartilage and the development of posttraumatic OA.
OBJECTIVE: To investigate whether cartilage degeneration is prevented or minimized following intraarticular injections of lubricin derived from human synoviocytes in culture, recombinant humanPRG4 (rhPRG4), or human synovial fluid (SF) in a rat model of anterior cruciate ligament (ACL) injury. METHODS: Unilateral ACL transection (ACLT) was performed in Lewis rats (n = 45). Nine animals were left untreated. The remaining rats were given intraarticular injections (50 microl/injection) of either phosphate buffered saline (PBS) (n = 9), human synoviocyte lubricin (200 microg/ml; n = 9), rhPRG4 (200 microg/ml; n = 9), or human SF lubricin (200 microg/ml; n = 9) twice weekly beginning on day 7 after injury. Joints were harvested on day 32 after injury. Histologic analysis was performed using Safranin O-fast green staining, and articular cartilage degeneration was graded using the Osteoarthritis Research Society International (OARSI)-modified Mankin criteria. Histologic specimens were immunoprobed for lubricin and sulfated glycosaminoglycans. A 24-hour urine collection was performed on days 17 and 29 postinjury, and urinary C-terminal telopeptide of type II collagen (CTX-II) levels were measured. RESULTS: Treatment with human synoviocyte lubricin resulted in significantly lower OARSI scores for cartilage degeneration compared with no treatment or PBS treatment (P < 0.05). Increased immunostaining for lubricin in the superficial zone chondrocytes and on the surface of cartilage was observed in lubricin-treated, but not untreated or PBS-treated, joints. On day 17, urinary CTX-II levels in human synoviocyte lubricin- and human SF lubricin-treated animals were significantly lower than those in untreated animals (P = 0.005 and P = 0.002, respectively) and in PBS-treated animals (P = 0.002 and P < 0.001, respectively). CONCLUSION: After treatment with any of the 3 types of lubricin evaluated in this study, a reduction in cartilage damage following ACLT was evident, combined with a reduction in type II collagen degradation. Our findings indicate that intraarticular lubricin injection following an ACL injury may be beneficial in retarding the degeneration of cartilage and the development of posttraumatic OA.
Authors: J Marcelino; J D Carpten; W M Suwairi; O M Gutierrez; S Schwartz; C Robbins; R Sood; I Makalowska; A Baxevanis; B Johnstone; R M Laxer; L Zemel; C A Kim; J K Herd; J Ihle; C Williams; M Johnson; V Raman; L G Alonso; D Brunoni; A Gerstein; N Papadopoulos; S A Bahabri; J M Trent; M L Warman Journal: Nat Genet Date: 1999-11 Impact factor: 38.330
Authors: Guoan Li; Jeremy M Moses; Ramprasad Papannagari; Neil P Pathare; Louis E DeFrate; Thomas J Gill Journal: J Bone Joint Surg Am Date: 2006-08 Impact factor: 5.284
Authors: K P H Pritzker; S Gay; S A Jimenez; K Ostergaard; J-P Pelletier; P A Revell; D Salter; W B van den Berg Journal: Osteoarthritis Cartilage Date: 2005-10-19 Impact factor: 6.576
Authors: Dongrim Seol; Daniel J McCabe; Hyeonghun Choe; Hongjun Zheng; Yin Yu; Keewoong Jang; Morgan W Walter; Abigail D Lehman; Lei Ding; Joseph A Buckwalter; James A Martin Journal: Arthritis Rheum Date: 2012-11
Authors: Ryosuke Sakata; Sean M McNary; Kazumasa Miyatake; Cassandra A Lee; James M Van den Bogaerde; Richard A Marder; A Hari Reddi Journal: Am J Sports Med Date: 2015-03-26 Impact factor: 6.202
Authors: Yu-Long Sun; Chunfeng Zhao; Gregory D Jay; Thomas M Schmid; Kai-Nan An; Peter C Amadio Journal: J Bone Joint Surg Am Date: 2013-02-06 Impact factor: 5.284
Authors: Edward D Bonnevie; Michelle L Delco; Lena R Bartell; Naveen Jasty; Itai Cohen; Lisa A Fortier; Lawrence J Bonassar Journal: J Biomech Date: 2018-04-25 Impact factor: 2.712
Authors: Mark Hurtig; Iman Zaghoul; Heather Sheardown; Tannin A Schmidt; Lina Liu; Ling Zhang; Khaled A Elsaid; Gregory D Jay Journal: J Orthop Res Date: 2018-12-17 Impact factor: 3.494
Authors: Parisa R Moshtagh; Nicoline M Korthagen; Saskia G Plomp; Behdad Pouran; Rene M Castelein; Amir A Zadpoor; Harrie Weinans Journal: JBMR Plus Date: 2018-01-31
Authors: Kimberly A Waller; Ling X Zhang; Khaled A Elsaid; Braden C Fleming; Matthew L Warman; Gregory D Jay Journal: Proc Natl Acad Sci U S A Date: 2013-03-25 Impact factor: 11.205
Authors: Shaowei Wang; Xiaochun Wei; Jingming Zhou; Jing Zhang; Kai Li; Qian Chen; Richard Terek; Braden C Fleming; Mary B Goldring; Michael G Ehrlich; Ge Zhang; Lei Wei Journal: Arthritis Rheumatol Date: 2014-07 Impact factor: 10.995